Upadacitinib in nail psoriasis: a case report

Abstract

The purpose of the article

Nail psoriasis is a refractory disease that affects 50–79% skin psoriasis patients and up to 80% of patients with psoriatic arthritis (PsA). The pathogenesis of nail psoriasis is still not fully illuminated, although some peculiar inflammatory cytokines and chemokines seems to be the same as described in psoriatic skin lesions. Treatment of nail psoriasis still with challenge and should be individualized. Upadacitinib, an oral highly selective JAK1 inhibitor, has been approved for PsA treatment. Whether it has the therapeutic advantages for nail psoriasis.

Results

We report a case of a patient with nail psoriasis who responded well to upadacitinib therapy at a dose of 15mg once daily for 5 months. In addition, we reviewed the literature and compared the current treatment efficiency in the treatment of nail psoriasis. The therapeutic effects of JAK inhibitors for nail psoriasis may involve downstream cytokines, such as I IL-6, IL-10, and IL-23.

Conclusion

Upadacitinib may be a promising therapeutic option for patients with severe nail psoriasis.

Keywords:

• Upadacitinib
• nail
• psoriasis
• biologics
• JAK inhibitor

Ethical approval

Informed written patient consent was taken from the patient.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

Data sharing is not applicable to this article.

Additional information

Funding

This work was funded by a grant award by Na Wang from the National Natural Science Foundation of China [81903230].